Logo

Innocare Announces the Results of P-II Study for TYK2 Inhibitor ICP-332 in Patients with Atopic Dermatitis

Share this
Innocare

Innocare Announces the Results of P-II Study for TYK2 Inhibitor ICP-332 in Patients with Atopic Dermatitis

Shots:

  • The P-II study evaluating safety, efficacy, PK and PD of ICP-332 in patients with moderate-to-severe atopic dermatitis
  • The result of the study demonstrated efficacy and safety in a 4-week treatment, achieving significant improvement in EASI scores, with a mean percentage change of 78.2% & 72.5% for 80mg & 120mg dosing groups, respectively
  • The study revealed ICP-332's positive impact on multiple efficacy endpoints incl. EASI 50, EASI 75, EASI 90, and IGA 0/1. The safety & tolerability of the drug were comparable to that of PBO

Ref: Innocare Image: Innocare

Related News:- InnoCare Receives IND Approval from NMPA to Initiate P-I Study of ICP-189 + Furmonertinib in NSCLC Patients

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Kritika Jha

Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions